GeneHealth - Your precision medicine

Pseudohypoparathyroidism Type 1b

Disease Details

Family Health Simplified

Buy Membership

Description: Pseudohypoparathyroidism type 1b is a genetic disorder characterized by the body's resistance to parathyroid hormone, leading to low calcium and high phosphate levels in the blood.
Type: Pseudohypoparathyroidism type 1b (PHP1B) is an inherited disorder. The type of genetic transmission for PHP1B is typically autosomal dominant with imprinting defects, usually involving the GNAS gene. This condition is often associated with epigenetic changes rather than direct mutations in the coding sequence of the gene.
Signs And Symptoms: Pseudohypoparathyroidism type 1b (PHP1b) primarily affects the body's ability to respond to parathyroid hormone (PTH), leading to a range of symptoms. Signs and symptoms of PHP1b include:

1. **Hypocalcemia**: Low blood calcium levels, which can lead to:
- Muscle cramps or spasms
- Tetany (involuntary muscle contractions)
- Numbness and tingling, especially in the face, hands, and feet
- Seizures in severe cases

2. **Hyperphosphatemia**: Elevated levels of phosphate in the blood.

3. **Resistance to PTH**: Despite normal or elevated levels of PTH, the body fails to respond properly, leading to the imbalances mentioned above.

4. **Renal issues**: Impaired renal tubular reabsorption of calcium might occur.

Individuals with PHP1b usually do not have the physical traits seen in other forms of pseudohypoparathyroidism (like Albright hereditary osteodystrophy in PHP1a), such as short stature, round face, or shortened metacarpal bones. The focus is on the biochemical and hormonal abnormalities.
Prognosis: Pseudohypoparathyroidism type 1b (PHP1b) generally has a good prognosis with appropriate medical management. The primary focus is on maintaining normal calcium and phosphate levels through oral supplementation and dietary adjustments. Regular monitoring and adherence to treatment protocols are crucial for preventing complications related to hypocalcemia and hyperphosphatemia. Quality of life can be significantly improved with proper endocrine care and support.
Onset: Pseudohypoparathyroidism type 1b typically has its onset in childhood or early adolescence. "Nan" refers to neurobehavioral, cognitive, and psychiatric issues often seen in affected individuals, including learning disabilities and developmental delays.
Prevalence: The prevalence of pseudohypoparathyroidism type 1b (PHP1b) is not well defined due to its rarity, but it is estimated to be about 0.79 per 100,000 people.
Epidemiology: Pseudohypoparathyroidism type 1b (PHP1B) is a rare genetic disorder characterized by resistance to the parathyroid hormone (PTH), leading to low serum calcium and high serum phosphate levels. The exact prevalence is not well-defined due to its rarity. It is inherited in an autosomal dominant manner and often involves genetic or epigenetic changes at the GNAS locus on chromosome 20q13. The incidence rate is not precisely known but is considered very low, with fewer cases reported in the medical literature compared to more common endocrine disorders.
Intractability: Pseudohypoparathyroidism type 1b (PHP1b) is considered a chronic condition that typically requires ongoing management rather than being curable. It is characterized by resistance to parathyroid hormone (PTH), leading to hypocalcemia and hyperphosphatemia. While the disease itself is intractable in terms of complete eradication, symptoms can often be controlled with appropriate medical treatment, such as calcium and vitamin D supplementation, to manage the biochemical abnormalities.
Disease Severity: Pseudohypoparathyroidism type 1b typically presents with mild to moderate severity. This condition is characterized by resistance to parathyroid hormone (PTH), leading to low calcium and high phosphate levels in the blood. Clinical manifestations may include tingling, muscle cramps, and occasional seizures due to hypocalcemia. However, unlike other subtypes of pseudohypoparathyroidism, it usually does not involve physical abnormalities, but the biochemical imbalances need to be managed to prevent complications.
Pathophysiology: Pseudohypoparathyroidism Type 1b (PHP1b) is a rare endocrine disorder characterized by resistance to the parathyroid hormone (PTH), which leads to low calcium levels and high phosphate levels in the blood despite normal or elevated PTH levels. The pathophysiology typically involves abnormalities in the GNAS gene, which encodes the Gs alpha subunit of the G protein. This subunit is critical for PTH signaling. In PHP1b, there is usually a methylation defect in the GNAS gene, affecting its expression and leading to impaired PTH receptor signaling in the kidneys and bones. This results in inadequate conversion of inactive vitamin D to its active form and poor calcium resorption, leading to hypocalcemia and hyperphosphatemia. Unlike other forms of pseudohypoparathyroidism, PHP1b does not typically present with physical features like Albright's hereditary osteodystrophy (AHO).
Carrier Status: Pseudohypoparathyroidism type 1b is generally inherited in an autosomal dominant pattern. Carrier status is not typically applicable in dominant conditions since having one copy of the altered gene is sufficient to cause the disorder. Unlike recessive disorders where individuals can be carriers without showing symptoms, affected individuals with pseudohypoparathyroidism type 1b typically exhibit symptoms if they inherit the altered gene.
Mechanism: Pseudohypoparathyroidism type 1b (PHP1b) is primarily characterized by resistance to parathyroid hormone (PTH), leading to features like hypocalcemia and hyperphosphatemia.

### Mechanism:
In PHP1b, there's a failure in the renal response to PTH. Normally, PTH binds to its receptor in the kidney, which activates the cAMP signaling pathway leading to increased calcium reabsorption and phosphate excretion. In PHP1b, this signaling is impaired, disrupting calcium and phosphate balance.

### Molecular Mechanisms:
PHP1b typically involves epigenetic changes on chromosome 20q13.3, where the GNAS gene is located. The GNAS gene encodes the Gαs protein, which plays a critical role in the PTH signaling pathway by stimulating the production of cAMP. In PHP1b:

- **Epigenetic Alterations**: There are often methylation defects in the GNAS complex locus. These can include loss of methylation at the exon A/B region, which affects the transcription of the GNAS gene.
- **GNAS Imprinting**: GNAS is an imprinted gene, meaning its expression is dependent on the parent of origin. Alterations in the imprinting control region (ICR) can disrupt normal GNAS expression, leading to deficient Gαs protein production and subsequent PTH resistance.

These molecular disruptions prevent the normal response to PTH in the kidney, manifesting in the clinical signs associated with PHP1b.
Treatment: For pseudohypoparathyroidism type 1b (PHP1B), treatment primarily involves addressing the biochemical abnormalities, particularly hypocalcemia and hyperphosphatemia. The main treatment strategies include:

1. **Calcium Supplements:** Oral calcium supplements are often prescribed to maintain normal calcium levels in the blood.

2. **Vitamin D Analogues:** Active forms of vitamin D, such as calcitriol or alfacalcidol, may be used to enhance calcium absorption from the gut.

3. **Phosphate Binders:** In some cases, phosphate binders may be prescribed to reduce high phosphate levels in the blood.

Regular monitoring of blood calcium and phosphate levels is essential to adjust treatment and avoid complications such as hypercalcemia or nephrocalcinosis. Consulting an endocrinologist for personalized management is recommended.
Compassionate Use Treatment: Pseudohypoparathyroidism type 1b (PHP1b) is a rare endocrine disorder characterized by resistance to the parathyroid hormone (PTH), leading to low calcium and elevated phosphate levels in the blood. There is no specific compassionate use treatment designated for PHP1b, but management typically focuses on correcting the biochemical abnormalities.

**Experimental or off-label treatments may include:**

1. **Calcitriol (Vitamin D analogs):** To help increase calcium absorption from the gut and decrease phosphate levels in the blood.
2. **Calcium supplements:** To ensure adequate calcium levels are maintained.
3. **Phosphate binders:** To reduce phosphate absorption from the intestine and lower blood phosphate levels.
4. **Magnesium supplements:** Sometimes used if magnesium levels are also low.

Research is ongoing, and clinical trials may offer additional insights into novel therapies. Consultation with an endocrinologist is essential for optimal management and consideration of experimental treatments.
Lifestyle Recommendations: For Pseudohypoparathyroidism Type 1b, lifestyle recommendations typically include:

1. **Regular Monitoring:** Routine check-ups with your healthcare provider to monitor calcium and phosphate levels.
2. **Diet:** A balanced diet rich in calcium (dairy products, leafy green vegetables, fortified foods) and low in phosphorus (avoid processed foods, cola drinks).
3. **Medications:** Adherence to prescribed medications, such as active vitamin D analogs and calcium supplements.
4. **Hydration:** Adequate fluid intake to maintain proper kidney function.
5. **Exercise:** Regular physical activity to help maintain bone strength and overall health.
6. **Sun Exposure:** Safely ensuring sufficient sunlight exposure to help with natural vitamin D synthesis, depending on geographic location and skin type.

Consult your healthcare provider for personalized advice and adjustments based on individual health needs.
Medication: Pseudohypoparathyroidism type 1b (PHP1b) is a rare genetic disorder characterized by resistance to parathyroid hormone (PTH). The primary goal of treatment is to manage hypocalcemia (low calcium levels) and hyperphosphatemia (high phosphate levels).

Medication options include:
1. **Calcium Supplements:** To maintain normal blood calcium levels.
2. **Active Vitamin D (Calcitriol):** To enhance calcium absorption from the gut.
3. **Phosphate Binders:** To reduce phosphate absorption in the intestines, thereby controlling serum phosphate levels.

Regular monitoring of serum calcium and phosphate levels is essential to adjust medication dosages appropriately.
Repurposable Drugs: Pseudohypoparathyroidism type 1b (PHP1B) is a rare genetic disorder primarily characterized by resistance to parathyroid hormone (PTH), leading to low calcium and high phosphate levels in the blood. Management generally focuses on normalizing calcium and phosphate levels rather than repurposing drugs. Treatment typically includes:

1. **Calcium Supplements**: To address hypocalcemia.
2. **Active Vitamin D Analogues**: Such as calcitriol, to enhance calcium absorption from the gut.
3. **Phosphate Binders**: In some cases, to reduce phosphate levels.

Currently, there are no specific repurposable drugs recognized for PHP1B that address the underlying genetic or hormonal resistance directly. Treatment remains supportive and focused on symptom management.
Metabolites: Pseudohypoparathyroidism type 1b (PHP1b) is a disorder characterized by resistance to the parathyroid hormone (PTH). Relevant metabolites in relation to PHP1b include:

1. **Calcium:** Typically low in the blood due to impaired response to PTH.
2. **Phosphate:** Usually elevated in the blood because of diminished renal excretion, which is a result of PTH resistance.
3. **Parathyroid Hormone (PTH):** Elevated due to the body's attempt to overcome the resistance and normalize calcium levels.
4. **Cyclic AMP (cAMP):** Often used to assess PTH receptor function, where PHP1b patients fail to show a rise in urinary cAMP after PTH administration.

This metabolic profile is crucial for diagnosing and managing PHP1b.
Nutraceuticals: For pseudohypoparathyroidism type 1b, there is no established role for nutraceuticals (dietary supplements with health benefits) in its management. This disorder typically requires medical interventions such as calcium and active vitamin D supplements to address hypocalcemia, rather than nutraceutical approaches. It is essential to follow a healthcare provider's guidance for treatment.
Peptides: Pseudohypoparathyroidism type 1b (PHP1b) is a genetic disorder characterized by the body's resistance to parathyroid hormone (PTH). As a result, levels of calcium are low and levels of phosphate are high in the blood.

In PHP1b, there is no known direct association with therapeutic peptides. Management typically involves addressing the imbalances of calcium and phosphate using supplements and other medications rather than using peptides.

Nan refers to nanometers, a unit of measure. In the context of PHP1b, nanoscale measurements might be relevant in research or diagnostic techniques but do not play a direct role in the standard clinical management of the disease utilizing conventional methods.